Details

Autor(en) / Beteiligte

• Chao, Jeffrey Yung-chuan
• Chang, Hsin-Chuan
• Jiang, Jeng-Kai
• Yang, Chih-Yung
• Chen, Fang-Hsin
• Lai, Yo-Liang
• Lin, Wen-Jen
• Li, Chia-Yang
• Wang, Shu-Chi
• Yang, Muh-Hwa
• Lin, Yu-Feng
• Cheng, Wei-Chung

Titel

Using bioinformatics approaches to investigate driver genes and identify BCL7A as a prognostic gene in colorectal cancer

Ist Teil von

• Computational and structural biotechnology journal, 2021-01, Vol.19, p.3922-3929

Ort / Verlag

Elsevier B.V

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• [Display omitted] Colorectal cancer (CRC) results from the uncontrolled growth of cells in the colon, rectum, or appendix. The 5-year relative survival rate for patients with CRC is 65% and is correlated with the stage at diagnosis (being 91% for stage I at diagnosis versus 12% for stage IV). This study aimed to identify CRC driver genes to assist in the design of a cancer panel to detect gene mutations during clinical early-stage screening and identify genes for use in prognostic assessments and the evaluation of appropriate treatment options. First, we utilized bioinformatics approaches to analyze 354 paired sequencing profiles from The Cancer Genome Atlas (TCGA) to identify CRC driver genes and analyzed the sequencing profiles of 38 patients with >5 years of follow-up data to search for prognostic genes. The results revealed eight driver genes and ten prognostic genes. Next, the presence of the identified gene mutations was verified using tissue and blood samples from Taiwanese CRC patients. The results showed that the set identified gene mutations provide high coverage for driver gene screening, and APC, TP53, PIK3CA, and FAT4 could be detected in blood as ctDNA test targets. We further found that BCL7A gene mutation was correlated with prognosis in CRC (log-rank p-value = 0.02), and that mutations of BCL7A could be identified in ctDNA samples. These findings may be of value in clinical early cancer detection, disease monitoring, drug development, and treatment efforts in the future.